- Home
- KGS vs HCM Comparison
KGS vs HCM Comparison
Compare KGS & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KGS | HCM |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | KGS | HCM |
|---|---|---|
| Price | $36.99 | $13.30 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $43.00 | $13.75 |
| AVG Volume (30 Days) | ★ 1.8M | 24.9K |
| Earning Date | 11-04-2025 | 08-07-2025 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | ★ 224.29 | N/A |
| EPS | ★ 0.84 | 0.53 |
| Revenue | ★ $1,284,748,000.00 | $602,197,000.00 |
| Revenue This Year | $13.95 | N/A |
| Revenue Next Year | $7.27 | $15.54 |
| P/E Ratio | $44.25 | ★ $5.02 |
| Revenue Growth | ★ 19.43 | N/A |
| 52 Week Low | $29.25 | $11.51 |
| 52 Week High | $50.43 | $19.50 |
Technical Indicators
Market Signals| Indicator | KGS | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 26.00 |
| Support Level | $35.73 | $14.11 |
| Resistance Level | $38.27 | $13.79 |
| Average True Range (ATR) | 1.00 | 0.21 |
| MACD | 0.26 | -0.06 |
| Stochastic Oscillator | 71.22 | 10.87 |
Price Performance
Historical ComparisonAbout KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.